A Phase 1 Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy
International Journal of Radiation Oncology*Biology*Physics · 2024
DOI: 10.1016/j.ijrobp.2024.02.014 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024. Verfasst von Krishnan R Patel und 12 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: Krishnan.Patel@nih.gov. Hauptthemen laut MEDLINE: Radiosurgery, Salvage Therapy, Prostatic Neoplasms, Brachytherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Intramural NIH HHS, National Institutes of Health, National Institutes of Health Mark O Hatfield Clinical Research Center.
Abstract (Originalsprache)
PURPOSE: NCT03253744 is a phase 1 trial with the primary objective to identify the maximum tolerated dose (MTD) of salvage stereotactic body radiation therapy (SBRT) in patients with local prostate cancer recurrence after brachytherapy. Additional objectives included biochemical control and imaging response. METHODS AND MATERIALS: This trial was initially designed to test 3 therapeutic dose levels (DLs): 40 Gy (DL1), 42.5 Gy (DL2), and 45 Gy (DL3) in 5 fractions. Intensity modulation was used to deliver the prescription dose to the magnetic resonance imaging and prostate-specific membrane antigen-based positron emission tomography imaging-defined gross tumor volume while simultaneously delivering 30 Gy to an elective volume defined by the prostate gland. This phase 1 trial followed a 3+3 design with a 3-patient expansion at the MTD. Toxicities were scored until trial completion at 2 years post-SBRT using Common Terminology Criteria for Adverse Events version 5.0. Escalation was halted if 2 dose limiting toxicities occurred, defined as any persistent (>4 days) grade 3 toxicity occurring within the first 3 weeks after SBRT or any grade ≥3 genitourinary (GU) or grade 4 gastrointestinal toxicity thereafter. RESULTS: Between August 2018 and January 2023, 9 patients underwent salvage SBRT and were observed for a median of 22 months (Q1-Q3, 20-43 months). No grade 3 to 5 adverse events related to study treatment were observed; thus, no dose limiting toxicities occurred during the observation period. Escalation was halted by amendment given excellent biochemical control in DL1 and DL2 in the setting of a high incidence of clinically significant late grade 2 GU toxicity. Therefore, the MTD was considered 42.5 Gy in 5 fractions (DL2). One- and 2-year biochemical progression-free survival were 100% and 86%, representing a single patient in the trial cohort with biochemical failure (prostate-specific antigen [PSA] nadir + 2.0) at 20 months posttreatment. CONCLUSIONS: The MTD of salvage SBRT for the treatment of intraprostatic radiorecurrence after brachytherapy was 42.5 Gy in 5 fractions producing an 86% 2-year biochemical progression-free survival rate, with 1 poststudy failure at 20 months. The most frequent clinically significant toxicity was late grade 2 GU toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: Krishnan.Patel@nih.gov.
- Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
- Biometric Research Program, National Cancer Institute, National Institutes of Health, Rockville, Maryland.
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Förderung
- Intramural NIH HHS
- National Institutes of Health
- National Institutes of Health Mark O Hatfield Clinical Research Center
Zitieren
APA
Patel, K. R., Rydzewski, N. R., Schott, E., Cooley-Zgela, T., Ning, H., Cheng, J., Salerno, K., Huang, E. P., Lindenberg, L., Mena, E., Choyke, P., Turkbey, B., & Citrin, D. E. (2024). A Phase 1 Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2024.02.014
Vancouver
Patel KR, Rydzewski NR, Schott E, Cooley-Zgela T, Ning H, Cheng J, et al. A Phase 1 Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy. International Journal of Radiation Oncology*Biology*Physics. 2024. doi:10.1016/j.ijrobp.2024.02.014
BibTeX
@article{Patel2024,
author = {Patel, Krishnan R and Rydzewski, Nicholas R and Schott, Erica and Cooley-Zgela, Theresa and Ning, Holly and Cheng, Jason and Salerno, Kilian and Huang, Erich P and Lindenberg, Liza and Mena, Esther and Choyke, Peter and Turkbey, Baris and Citrin, Deborah E},
title = {A Phase 1 Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2024},
doi = {10.1016/j.ijrobp.2024.02.014}
}
EUVIMED